- Home
- INCY
INCY
Incyte Corp.
as 12-26-2024 4:00pm EST
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | N/A | IPO Year: | 1993 |
| Target Price: | $75.44 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -92.12 |
| 52 Week Low/High: | $50.35 - $83.95 | Next Earning Date: | 02-11-2025 |
| Revenue: | $4,075,860,000 | Revenue Growth: | 12.94% |
| Revenue Growth (this year): | 16.03% | Revenue Growth (next year): | 10.35% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tray Thomas | INCY | Principal Accounting Officer | Dec 13 '24 | Sell | $69.98 | 1,300 | $90,967.50 | 23,962 | |
| Iyengar Vijay K | INCY | EVP, GMAPPS | Nov 29 '24 | Sell | $75.49 | 6,043 | $455,543.71 | 36,341 | |
| Flannelly Barry P | INCY | EVP & General Manager US | Nov 6 '24 | Sell | $80.10 | 3,680 | $293,209.76 | 60,298 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
TipRanks
7 days ago
Incyte price target raised to $70 from $68 at Wells Fargo
Zacks
7 days ago
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
MT Newswires
7 days ago
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
MT Newswires
9 days ago
UBS Initiates Coverage on Incyte With Neutral Rating, $77 Price Target
Business Wire
9 days ago
Incyte to Present at Upcoming Investor Conference
MT Newswires
10 days ago
Leerink Adjusts Price Target on Incyte to $100 From $87, Maintains Outperform Rating
Clinical Trials Arena
15 days ago
ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.